E2F1 and non-small cell lung carcinoma: E2F1 is overexpressed in solid cancers, including non-small cell lung carcinoma, ovarian, prostate, and bladder cancers, colon cancer, and other digestive system malignances, and is associated with worse patient prognosis [27], [28], [29], [30], [31], [32], [33], [34], [35], [36].